Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. (May 2019)
- Record Type:
- Journal Article
- Title:
- Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. (May 2019)
- Main Title:
- Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study
- Authors:
- Woo, Peter Y.M.
Ho, Jason M.K.
Tse, Teresa P.K.
Lam, Sandy W.
Mak, Calvin H.K.
Chan, Danny T.M.
Lee, Michael W.Y.
Wong, Sui-To
Chan, Kwong-Yau
Poon, Wai-Sang - Abstract:
- Highlights: Glioblastoma volumetric analysis of extent of resection can predict overall survival. Achieving an extent of resection of 84% or more imparts an overall survival benefit. A residual tumor volume of less than 3.50 cc is independently associated with longer overall survival. Residual tumor volumes may be a more accurate survival predictor than extent of resection. Glioblastoma promoter MGMT methylation remains a robust survival prognosticator. Abstract: Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy. Although extent of resection (EOR) is a well-known surgical predictor for overall survival most lesions cannot be completely resected. We hypothesize that in the event of incomplete resection, residual tumor volume (RTV) may be a more significant predictor than EOR. This was a multicenter retrospective review of 147 adult glioblastoma patients (mean age 53 years) that underwent standard treatment. Semiautomatic magnetic resonance imaging segmentation was performed for pre- and postoperative scans for volumetric analysis. Cox proportional hazards regression and Kaplan-Meier survival analyses were performed for prognostic factors including: age, Karnofsky performance score (KPS), O(6)-methylguanine methyltransferase ( MGMT ) promoter methylation status, EOR and RTV. EOR and RTV cut-off values for improved OS were determined and internally validated by receiver operator characteristic (ROC) analysisHighlights: Glioblastoma volumetric analysis of extent of resection can predict overall survival. Achieving an extent of resection of 84% or more imparts an overall survival benefit. A residual tumor volume of less than 3.50 cc is independently associated with longer overall survival. Residual tumor volumes may be a more accurate survival predictor than extent of resection. Glioblastoma promoter MGMT methylation remains a robust survival prognosticator. Abstract: Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy. Although extent of resection (EOR) is a well-known surgical predictor for overall survival most lesions cannot be completely resected. We hypothesize that in the event of incomplete resection, residual tumor volume (RTV) may be a more significant predictor than EOR. This was a multicenter retrospective review of 147 adult glioblastoma patients (mean age 53 years) that underwent standard treatment. Semiautomatic magnetic resonance imaging segmentation was performed for pre- and postoperative scans for volumetric analysis. Cox proportional hazards regression and Kaplan-Meier survival analyses were performed for prognostic factors including: age, Karnofsky performance score (KPS), O(6)-methylguanine methyltransferase ( MGMT ) promoter methylation status, EOR and RTV. EOR and RTV cut-off values for improved OS were determined and internally validated by receiver operator characteristic (ROC) analysis for 12-month overall survival. Half of the tumors had MGMT promoter methylation (77, 52%). The median tumor volume, EOR and RTV were 43.20 cc, 93.5%, and 3.80 cc respectively. Gross total resection was achieved in 52 patients (35%). Cox proportional hazards regression, ROC and maximum Youden index analyses for RTV and EOR showed that a cut-off value of <3.50 cc (HR 0.69; 95% CI 0.48–0.98) and ≥84% (HR 0.64; 95% CI 0.43–0.96) respectively conferred an overall survival advantage. Independent overall survival predictors were MGMT promoter methylation (adjusted HR 0.35; 95% CI 0.23–0.55) and a RTV of <3.50 cc (adjusted HR 0.53; 95% CI 0.29–0.95), but not EOR for incompletely resected glioblastomas. … (more)
- Is Part Of:
- Journal of clinical neuroscience. Volume 63(2019)
- Journal:
- Journal of clinical neuroscience
- Issue:
- Volume 63(2019)
- Issue Display:
- Volume 63, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 63
- Issue:
- 2019
- Issue Sort Value:
- 2019-0063-2019-0000
- Page Start:
- 134
- Page End:
- 141
- Publication Date:
- 2019-05
- Subjects:
- Glioblastoma -- Extent of resection -- Residual tumor volume -- Overall survival -- Temozolomide chemo-radiotherapy -- Volumetric analysis
Brain -- Surgery -- Periodicals
Neurosciences -- Periodicals
Nervous system -- Surgery -- Periodicals
Brain -- surgery -- Periodicals
Neurosurgical Procedures -- Periodicals
Neurosciences -- Periodicals
Electronic journals
616.8 - Journal URLs:
- http://www.harcourt-international.com/journals ↗
http://www.sciencedirect.com/science/journal/09675868 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09675868 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.jocn.2019.01.022 ↗
- Languages:
- English
- ISSNs:
- 0967-5868
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4958.585000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9828.xml